SHILPAMED Shilpa Medicare Ltd Operational Disruptions Announcement 2023 - MHRA Approval for Betahistine Dihydrochloride Orodispersible Films, 24 mg Shilpa Medicare Ltd. has received approval from MHRA, UK, for Betahistine Dihydrochloride Orodispersible Films, 24 mg, making it the first company to receive approval for this strength in the UK. This approval is for a prescription Oral Film product manufactured at the companys facility in Bengaluru, Karnataka..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Shilpa Medicare Ltd